CRISPR Therapeutics
Logotype for CRISPR Therapeutics AG

CRISPR Therapeutics (CRSP) investor relations material

CRISPR Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for CRISPR Therapeutics AG
Jefferies Global Healthcare Conference summary17 Nov, 2026

Portfolio and pipeline

  • Portfolio spans CASGEVY, later-stage CTX310, zugo-cel and CTX611, plus earlier programs including A1AT, CTX340, type 1 diabetes, in vivo CAR T and in vivo HSC editing.

  • CTX310, zugo-cel and CTX611 could enter late-stage trials within about a year; the 2027 outlook includes continued portfolio progression and potential early CTX340 and A1AT data.

CTX310

  • In severe hypertriglyceridemia, CTX310 showed a mean triglyceride reduction close to 65%; 8 of 10 patients were below 500 at day 28, a threshold associated with reducing pancreatitis risk.

  • LDL, ApoB and non-HDL cholesterol also declined, which was presented as a differentiation from APOC3 approaches; responses had deepened over time in early observations.

  • The one-time ANGPTL3 treatment produced durable lipid reductions through one year in earlier data; further data are expected on glucose control and hepatic fat in the coming year.

  • RMAT designations cover severe hypertriglyceridemia and LDL reduction; management aims to advance quickly toward late-stage trials, with an FDA RMAT meeting expected to help shape a potential Phase III design.

  • Severe hypertriglyceridemia is the initial development path; mixed dyslipidemia and homozygous familial hypercholesterolemia, including patients with inadequate PCSK9 response, are also potential trial settings.

Zugo-cel

  • Zugo-cel is an allogeneic CD19 CAR T with CRISPR edits intended to drive potent expansion while cells are cleared; management sees transient persistence as potentially advantageous for autoimmune disease.

  • In the scleroderma cohort, 6 of 7 patients had an early CRISS-25 response; the 2 patients beyond six months had CRISS-50 responses, with responses reported to deepen over time.

  • Three patients had interstitial lung disease at baseline; no continued decline was observed, and some rapidly progressing patients stabilized. Lung-function improvement may take beyond month six; an update could come in 2027.

  • Trials include lupus, myositis and scleroderma, with neuroimmune indications added; management plans to increase the dose after limited expansion in some patients and cited COGS below $10,000 per patient.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next CRISPR Therapeutics earnings date

Logotype for CRISPR Therapeutics AG
Q4 202612 Feb, 2027
CRISPR Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next CRISPR Therapeutics earnings date

Logotype for CRISPR Therapeutics AG
Q4 202612 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Transforming medicine

CRISPR-Cas9 had its initial description ten years ago when a study revealed the potential of exploiting the system for RNA-programmable gene editing. It allows scientists to change the molecules that carry the instructions to produce proteins without changing the original DNA code.

The technology has its foundation in the natural defense mechanism of bacteria and single-celled microorganisms. When mentioned, CRISPR often links to Cas9, the protein that helps target and cut the genetic code to be edited. You can therefore see Cas9 as the genetic scissors cutting the DNA at a specific point, and once the gene is cut, there are two possible outcomes:

  1. The cell repairs itself.

  2. The researchers insert a new DNA template for the repair.

A true gene editing enabler?

CRISPR technology is transforming medicine, enabling us to treat and prevent many diseases. It also has the potential to be used to make precise changes, such as replacing faulty genes – true gene editing.

We have seen remarkable progress within this technology in the first ten years. As new editing technologies develop, we can insert larger DNA fragments more precisely, enabling us to tackle more of the 75,000 genetic variants associated with human disease. Some of CRISPR’s main competitors include Intellia Therapeutics, Denali Therapeutics, Vaxcyte, and Ginkgo Bioworks.